Search

Your search keyword '"Junichi Inokuchi"' showing total 124 results

Search Constraints

Start Over You searched for: Author "Junichi Inokuchi" Remove constraint Author: "Junichi Inokuchi" Topic business.industry Remove constraint Topic: business.industry
124 results on '"Junichi Inokuchi"'

Search Results

1. Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer

2. Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study

3. Impact of the objective response to and number of cycles of platinum‐based first‐line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab

4. Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort

5. Clinical advantages of robot‐assisted partial nephrectomy versus laparoscopic partial nephrectomy in terms of global and split renal functions: A propensity score‐matched comparative analysis

6. Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer

7. Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy: a case report

8. Gene amplification ofYB‐1in castration‐resistant prostate cancer in association with aberrant androgen receptor expression

9. Effect of Smoking on Oncological Outcome among Prostate Cancer Patients after Radical Prostatectomy with Neoadjuvant Hormonal Therapy

10. Impact of antiandrogen withdrawal syndrome in castration‐resistant prostate cancer patients treated with abiraterone or enzalutamide

11. Surgical Navigation Improves Renal Parenchyma Volume Preservation in Robot-Assisted Partial Nephrectomy: A Propensity Score Matched Comparative Analysis

12. Thickness of Perirenal Fat Predicts the Growth Pattern of Renal Cell Carcinoma

13. Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer

14. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

15. Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer

16. MP24-16 PSOAS MUSCLE VOLUME IS A PREDICTIVE MARKER OF APPETITE LOSS IN PROSTATE CANCER PATIENTS TREATED WITH ENZALUTAMIDE

17. MP63-19 CORRELATION BETWEEN PELVIC LYMPH NODE DISSECTION AND URINARY INCONTINENCE AFTER ROBOT ASSISTED RADICAL PROSTATECTOMY

18. PD47-09 DEEP LEARNING SYSTEM FOR AUTOMATIC DETECTION OF BLADDER TUMORS IN NARROW-BAND IMAGING (NBI) CYSTOSCOPIC IMAGES

19. Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients

20. Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men

21. Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer

22. Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy

23. Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma

24. The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men

25. Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer

26. Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer

27. Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study

28. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study

29. Prognostic impact of prior local therapy in castration-resistant prostate cancer

30. Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: Results from a prospective cohort in the PRIAS-JAPAN study

32. Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer

33. The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study

34. Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone

35. Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer

36. The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle invasive bladder cancer in a genome-wide association study

37. Identification of Activated Protein Kinase Cα (PKCα) in the Urine of Orthotopic Bladder Cancer Xenograft Model as a Potential Biomarker for the Diagnosis of Bladder Cancer

38. Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors

39. Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A

40. Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor

41. Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper

42. Perioperative therapies for urological cancers

43. Uptake of 18F-FDG in Adrenal Adenomas Is Associated With Unenhanced CT Value and Constituent Cells

44. Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

45. Psoas muscle volume is correlated with sexual activity and erectile dysfunction among patients with localised prostate cancer

46. Thick perirenal fat predicts the growth pattern of renal cell carcinoma

47. Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer

48. The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?

49. Laparoscopic Versus Open Nephroureterectomy in Muscle-Invasive Upper Tract Urothelial Carcinoma: Subanalysis of the Multi-Institutional National Database of the Japanese Urological Association

50. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism

Catalog

Books, media, physical & digital resources